Pfizer and BioNTech Announce an Agreement with U. S. Government for up to 600 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
22 juil. 2020 07h10 HE
|
BioNTech SE; Pfizer Inc.
U. S. government placed an initial order of 100 million doses for $1.95 billion and can acquire up to 500 million additional dosesAmericans to receive the vaccine for free consistent with U.S....
AXIM® Biotechnologies Welcomes Former Secretary of Veterans Affairs Peter O'Rourke to Company’s Board of Directors
21 juil. 2020 09h00 HE
|
AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, July 21, 2020 (GLOBE NEWSWIRE) -- AXIM® Biotechnologies, Inc. (OTCQB: AXIM) ("AXIM® Biotech," "AXIM" or "the Company"), an international healthcare solutions company targeting oncological...
Pfizer und BioNTech veröffentlichen erste positive Daten aus laufender deutscher Phase-1/2-COVID-19-Impfstoffstudie samt vorläufigen Ergebnissen zur T-Zell-Antwort
20 juil. 2020 08h45 HE
|
BioNTech SE
Die Daten zeigen erneut, dass BNT162b1 hohe SARS-CoV-2-neutralisierende Antikörpertiter induziert.BNT162b1 rief, verglichen mit dem Ausgangswert bei Studienbeginn, starke CD4+ und CD8+...
Pfizer and BioNTech Announce Early Positive Update from German Phase 1/2 COVID-19 Vaccine Study, Including First T Cell Response Data
20 juil. 2020 08h45 HE
|
BioNTech SE
The data further demonstrated the ability of BNT162b1 to elicit high SARS-CoV-2 neutralizing titersBNT162b1 elicited strong CD4+ and CD8+ T cell responses against SARS-CoV-2- receptor binding domain...
Innovation Pharmaceuticals’ Brilacidin Inhibits Novel Coronavirus (COVID-19) by Almost 90% at the Lowest Concentration Tested to Date in a Human Lung Cell Line
20 juil. 2020 07h30 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 20, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, reports today receiving new data from ongoing...
Pfizer und BioNTech geben Vereinbarung mit dem Vereinigten Königreich über 30 Millionen Dosen eines mRNA-basierten Impfstoffkandidaten gegen SARS-CoV-2 bekannt
20 juil. 2020 01h00 HE
|
BioNTech SE
30 Millionen Dosen werden voraussichtlich 2020 und 2021 geliefert, vorbehaltlich der behördlichen Genehmigung oder ZulassungPfizer und BioNTech sind im Zeitplan, noch diesen Monat die erwartete...
Pfizer and BioNTech Announce Agreement with the United Kingdom for 30 Million Doses of mRNA-based Vaccine Candidate Against SARS-CoV-2
20 juil. 2020 01h00 HE
|
BioNTech SE
Thirty million doses expected to be delivered in 2020 and 2021, subject to regulatory approval or authorizationPfizer and BioNTech remain on track to begin an anticipated Phase 2b/3 safety and...
Innovation Pharmaceuticals – Clinical Trial Testing of Brilacidin Against SARS-CoV-2 (COVID-19) Targeted to Commence Q4 2020
13 juil. 2020 08h00 HE
|
Innovation Pharmaceuticals Inc.
WAKEFIELD, Mass., July 13, 2020 (GLOBE NEWSWIRE) -- Innovation Pharmaceuticals (OTCQB:IPIX) (“the Company”), a clinical stage biopharmaceutical company, today provides perspectives on the planned...
Pfizer und BioNTech erhalten FDA-Fast-Track-Status für zwei mRNA-basierte Impfstoffkandidaten gegen SARS-CoV-2
13 juil. 2020 06h45 HE
|
BioNTech SE
NEW YORK und MAINZ, Deutschland, July 13, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) und BioNTech SE (Nasdaq: BNTX, „BioNTech”) gaben heute bekannt, dass zwei der vier in Entwicklung...
Pfizer and BioNTech Granted FDA Fast Track Designation for Two Investigational mRNA-based Vaccine Candidates Against SARS-CoV-2
13 juil. 2020 06h45 HE
|
BioNTech SE
NEW YORK and MAINZ, Germany, July 13, 2020 (GLOBE NEWSWIRE) -- Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced that two of the companies’ four investigational...